Circadian changes direction

By Dylan Bushell-Embling
Thursday, 12 June, 2008

Australian biotechnology firm Circadian Technologies (ASX: CIR) is restructuring and plans to evolve from a biotech incubator to a drug development company which will specialise in cancer treatments.

Circadian has appointed a product development review group, which includes both the former head of development and the former project team leader from US biotech Amgen.

The group will oversee the company's commercialisation of cancer treatment drugs based on its VEGF inhibitors, developed by subsidiary Vegenics.

Content from other channels on our network

Know Your Grocery Code program for fresh food suppliers to supermarkets

2026 PIDA Award Finalists announced

AMS announces 2026 Beamex User Group meeting

Singapore, a hub for European dairy in SE Asia

Taste perception study to help advance functional food designs

AMS announces 2026 Beamex User Group meeting

A high-speed, real-time optical data connection for industrial applications

Redesigning for decarbonisation: the shift towards electrified hydraulic power

Chinese humanoid robot manufacturer opens mass production plant

A guide to a cost-effective SIS

Six key pillars of frailty prevention and management

Protecting the people who protect us: PPE continuity during demand surge

WA steps in to ensure 'continuity' of operations at Mount Private Hospital

What healthcare boards need from risk leaders

Additional $22.9m in research grants for nation's biggest killer

Circadian changes direction

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network